Today, many virus vectors have demonstrated promising efficacy in combination with standard melanoma therapy, including immunotherapy, either in the form of MEK and BRAF inhibitors or in combination with chemotherapy (dacarbazine and cisplatin). This evidence concerns the gene MAP2K7 and melanoma.